<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SOLU-CORTEF- hydrocortisone sodium succinate injection, powder, for solution </strong><br>Cardinal Health<br></p></div>
<h1>SOLU-CORTEF<span class="Sup">®</span> (hydrocortisone sodium succinate for injection, USP)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_18c0d9fc-7b6e-4f9a-947d-50bfe9943043"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">NOT FOR USE IN NEONATES</span></p>
<p><span class="Bold">CONTAINS BENZYL ALCOHOL</span></p>
<p><span class="Bold">For Intravenous or Intramuscular Administration</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_59ac6866-1dec-4b03-ba56-f00b9ede9cd1"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">SOLU-CORTEF Sterile Powder is an anti-inflammatory glucocorticoid, which contains hydrocortisone sodium succinate as the active ingredient. SOLU-CORTEF Sterile Powder is available in several packages for intravenous or intramuscular administration.</p>
<a name="id_bbb2ef1a-3396-4bb4-bd6a-f2f28f411448"></a><table>
<col align="left" width="28%">
<col align="center" width="18%">
<col align="center" width="18%">
<col align="center" width="18%">
<col align="center" width="18%">
<thead>
<tr class="First Toprule"><td class="Botrule Lrule" align="left" colspan="5" valign="top"> ACT-O-VIAL<span class="Sup">®</span> System (Single-Dose Vial) in four strengths: </td></tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"> 100 mg <br> ACT-O-VIAL</td>
<td class="Botrule Rrule" align="left" valign="top"> 250 mg <br> ACT-O-VIAL</td>
<td class="Botrule Rrule" align="left" valign="top"> 500 mg <br> ACT-O-VIAL</td>
<td class="Botrule Lrule" align="left" valign="top"> 1000 mg <br> ACT-O-VIAL</td>
</tr>
<tr class="Botrule Last">
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">Each 2 mL<br> contains:<br> (when mixed)</td>
<td class="Rrule" align="left" valign="top">Each 2 mL<br> contains:<br> (when mixed)</td>
<td class="Rrule" align="left" valign="top">Each 4 mL<br> contains:<br> (when mixed)</td>
<td align="left" valign="top">Each 8 mL<br> contains:<br> (when mixed)</td>
</tr>
</thead>
<tbody>
<tr class="First Toprule">
<td align="left" valign="top">Hydrocortisone<br>  sodium succinate</td>
<td class="Toprule" align="left" valign="top">equiv. to<br> 100 mg<br> Hydrocortisone</td>
<td class="Toprule" align="left" valign="top">equiv. to<br> 250 mg<br> Hydrocortisone</td>
<td class="Toprule" align="left" valign="top">equiv. to<br> 500 mg<br> Hydrocortisone</td>
<td align="left" valign="top">equiv. to<br> 1000 mg<br> Hydrocortisone</td>
</tr>
<tr>
<td align="left" valign="top">Monobasic sodium<br>  phosphate anhydrous</td>
<td align="left" valign="top">0.8 mg</td>
<td align="left" valign="top">2 mg</td>
<td align="left" valign="top">4 mg</td>
<td align="left" valign="top">8 mg</td>
</tr>
<tr>
<td align="left" valign="top">Dibasic sodium<br>  phosphate dried</td>
<td align="left" valign="top">8.73 mg</td>
<td align="left" valign="top">21.8 mg</td>
<td align="left" valign="top">44 mg</td>
<td align="left" valign="top">87.32 mg</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">Benzyl alcohol<br>  added as preservative</td>
<td align="left" valign="top">18.1 mg</td>
<td align="left" valign="top">16.4 mg</td>
<td align="left" valign="top">33.4 mg</td>
<td align="left" valign="top">66.9 mg</td>
</tr>
</tbody>
</table>
<p>When necessary, the pH of each formula was adjusted with sodium hydroxide so that the pH of the reconstituted solution is within the USP specified range of 7 to 8.</p>
<p>The chemical name for hydrocortisone sodium succinate is pregn-4-ene-3,20-dione,21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, monosodium salt, (11β)- and its molecular weight is 484.52.</p>
<p>The structural formula is represented below:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2b4c961-363d-49fe-b354-d59b39fd517a&amp;name=b2b4c961-363d-49fe-b354-d59b39fd517a-01.jpg"></div>
<p>Hydrocortisone sodium succinate is a white or nearly white, odorless, hygroscopic amorphous solid. It is very soluble in water and in alcohol, very slightly soluble in acetone and insoluble in chloroform.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_15624a44-0b89-4504-8a8b-4d647757d6df"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract.</p>
<p>Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their anti-inflammatory effects in disorders of many organ systems.</p>
<p>Hydrocortisone sodium succinate has the same metabolic and anti-inflammatory actions as hydrocortisone. When given parenterally and in equimolar quantities, the two compounds are equivalent in biologic activity. The highly water-soluble sodium succinate ester of hydrocortisone permits the immediate intravenous administration of high doses of hydrocortisone in a small volume of diluent and is particularly useful where high blood levels of hydrocortisone are required rapidly. Following the intravenous injection of hydrocortisone sodium succinate, demonstrable effects are evident within one hour and persist for a variable period. Excretion of the administered dose is nearly complete within 12 hours. Thus, if constantly high blood levels are required, injections should be made every 4 to 6 hours. This preparation is also rapidly absorbed when administered intramuscularly and is excreted in a pattern similar to that observed after intravenous injection.</p>
<p>Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body's immune response to diverse stimuli.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_c57853f0-2d31-44c6-bc89-b72eef20be8d"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the <span class="Bold">intravenous or intramuscular use</span> of SOLU-CORTEF Sterile Powder is indicated as follows: </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f5e7fde1-55da-45e3-8a98-8c871f9a89a7"></a><a name="section-4.1"></a><p></p>
<h2>Allergic states</h2>
<p class="First">Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span> reactions, perennial or <span class="product-label-link" type="condition" conceptid="4280726" conceptname="Seasonal allergic rhinitis">seasonal allergic rhinitis</span>, <span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>, <span class="product-label-link" type="condition" conceptid="440603" conceptname="Blood transfusion reaction">transfusion reactions</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_df4044e0-0e08-4ef2-96fe-363a152d4e32"></a><a name="section-4.2"></a><p></p>
<h2>Dermatologic diseases</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="137944" conceptname="Bullous dermatosis">Bullous dermatitis</span> herpetiformis, exfoliative <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">erythroderma</span>, <span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">mycosis fungoides</span>, <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>, severe <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span> (<span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6ac367ff-14f1-4d46-b1b3-2f5de36ed378"></a><a name="section-4.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine disorders</span></h2>
<p class="First">Primary or <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span>, <span class="product-label-link" type="condition" conceptid="435511" conceptname="Hypercalcemia">hypercalcemia</span> associated with cancer, nonsuppurative <span class="product-label-link" type="condition" conceptid="133444" conceptname="Thyroiditis">thyroiditis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6a8c0405-984a-465b-883c-0d60f0e37a83"></a><a name="section-4.4"></a><p></p>
<h2>Gastrointestinal diseases</h2>
<p class="First">To tide the patient over a critical period of the disease in <span class="product-label-link" type="condition" conceptid="201606" conceptname="Crohn's disease">regional enteritis</span> (systemic therapy) and <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b8a2a6d4-12f4-41a1-85a4-1816d4aeb641"></a><a name="section-4.5"></a><p></p>
<h2>Hematologic disorders</h2>
<p class="First">Acquired (autoimmune) <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, congenital (erythroid) <span class="product-label-link" type="condition" conceptid="4218974" conceptname="Hypoplastic anemia">hypoplastic anemia</span> (Diamond-Blackfan <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>), <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span> in adults (intravenous administration only; intramuscular administration is contraindicated), pure <span class="product-label-link" type="condition" conceptid="4226622" conceptname="Decreased erythroid precursor production">red cell aplasia</span>, selected cases of secondary <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_20561ea0-f774-4fb8-bc16-9129826406df"></a><a name="section-4.6"></a><p></p>
<h2>Miscellaneous</h2>
<p class="First">Trichinosis with neurologic or myocardial involvement, tuberculous <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2d3961b8-a724-4728-8f9f-438781b85994"></a><a name="section-4.7"></a><p></p>
<h2>Neoplastic diseases</h2>
<p class="First">For the palliative management of <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a5c01018-3798-45bd-b352-17324718447e"></a><a name="section-4.8"></a><p></p>
<h2>Nervous System</h2>
<p class="First">Acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>; <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span> associated with primary or metastatic <span class="product-label-link" type="condition" conceptid="4116092" conceptname="Intracranial tumor">brain tumor</span>, or craniotomy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b3f243e6-ef34-4d31-8aeb-a509877b298c"></a><a name="section-4.9"></a><p></p>
<h2>Ophthalmic diseases</h2>
<p class="First">Sympathetic ophthalmia, <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> and ocular inflammatory conditions unresponsive to topical corticosteroids.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_52c93e8a-cacf-4cc3-9a8c-45add152257e"></a><a name="section-4.10"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal diseases</span></h2>
<p class="First">To induce <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or remission of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> in idiopathic <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> or that due to <span class="product-label-link" type="condition" conceptid="255891" conceptname="Lupus erythematosus">lupus erythematosus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_03dce54b-e270-4862-8b0e-c20f9170abfe"></a><a name="section-4.11"></a><p></p>
<h2>Respiratory diseases</h2>
<p class="First">Berylliosis, fulminating or disseminated <span class="product-label-link" type="condition" conceptid="253954" conceptname="Pulmonary tuberculosis">pulmonary tuberculosis</span> when used concurrently with appropriate antituberculous chemotherapy, idiopathic <span class="product-label-link" type="condition" conceptid="4279553" conceptname="Eosinophilic asthma">eosinophilic pneumonias</span>, symptomatic <span class="product-label-link" type="condition" conceptid="438688" conceptname="Sarcoidosis">sarcoidosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a439a52a-7c58-4c9a-bbc5-e18e79ec6d65"></a><a name="section-4.12"></a><p></p>
<h2>Rheumatic disorders</h2>
<p class="First">As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute <span class="product-label-link" type="condition" conceptid="74892" conceptname="Articular gout">gouty arthritis</span>; acute rheumatic carditis; <span class="product-label-link" type="condition" conceptid="437082" conceptname="Ankylosing spondylitis">ankylosing spondylitis</span>; <span class="product-label-link" type="condition" conceptid="81931" conceptname="Psoriasis with arthropathy">psoriatic arthritis</span>; <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, including <span class="product-label-link" type="condition" conceptid="4253901" conceptname="Juvenile rheumatoid arthritis">juvenile rheumatoid arthritis</span> (selected cases may require low-dose maintenance therapy). For the treatment of <span class="product-label-link" type="condition" conceptid="80182" conceptname="Dermatomyositis">dermatomyositis</span>, <span class="product-label-link" type="condition" conceptid="4290976" conceptname="Temporal arteritis">temporal arteritis</span>, <span class="product-label-link" type="condition" conceptid="80800" conceptname="Polymyositis">polymyositis</span>, and <span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">systemic lupus erythematosus</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_2d461d45-2cd3-4efc-b04c-1d6c43d36f9d"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">SOLU-CORTEF Sterile Powder is contraindicated in systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> and patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the product and its constituents. </p>
<p>Intramuscular corticosteroid preparations are contraindicated for <span class="product-label-link" type="condition" conceptid="4120621" conceptname="Immune thrombocytopenic purpura">idiopathic thrombocytopenic purpura</span>. </p>
<p>SOLU-CORTEF Sterile Powder is contraindicated for use in premature infants because the formulation contains benzyl alcohol. (See <span class="Bold"><a href="#i4i_warnings_id_294eea5c-daf0-43f7-88d9-5ecf0c3316c1">WARNINGS</a></span> and <span class="Bold"><a href="#i4i_pediatric_use_id_42eebec1-6791-4987-909c-1a3a1bc4f1ca">PRECAUTIONS: Pediatric Use</a></span>.)</p>
<p>SOLU-CORTEF Sterile Powder is contraindicated for intrathecal administration. Reports of severe medical events have been associated with this route of administration.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_294eea5c-daf0-43f7-88d9-5ecf0c3316c1"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d049765f-c1cd-443c-9cac-d1f60bc91de3"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">This product contains benzyl alcohol which is potentially toxic when administered locally to neural tissue. Exposure to excessive amounts of benzyl alcohol has been associated with toxicity (<span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>), particularly in neonates, and an increased incidence of <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span>, particularly in small preterm infants. There have been rare reports of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, primarily in preterm infants, associated with exposure to excessive amounts of benzyl alcohol. The amount of benzyl alcohol from medications is usually considered negligible compared to that received in flush solutions containing benzyl alcohol. Administration of high dosages of medications containing this preservative must take into account the total amount of benzyl alcohol administered. The amount of benzyl alcohol at which toxicity may occur is not known. If the patient requires more than the recommended dosages or other medications containing this preservative, the practitioner must consider the daily metabolic load of benzyl alcohol from these combined sources (see <span class="Bold"><a href="#i4i_warnings_id_294eea5c-daf0-43f7-88d9-5ecf0c3316c1">WARNINGS</a></span> and <span class="Bold"><a href="#i4i_pediatric_use_id_42eebec1-6791-4987-909c-1a3a1bc4f1ca">PRECAUTIONS: Pediatric Use</a></span>).</p>
<p>Injection of SOLU-CORTEF may result in dermal and/or subdermal changes forming <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depressions</span> in the skin at the injection site. In order to minimize the incidence of dermal and subdermal <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, care must be exercised not to exceed recommended doses in injections. Injection into the deltoid muscle should be avoided because of a high incidence of subcutaneous <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>.</p>
<p>Rare instances of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in patients receiving corticosteroid therapy (see <span class="Bold"><a href="#i4i_adverse_effects_id_12835ccc-8444-40f7-b89b-2463e6c472e0">ADVERSE REACTIONS</a></span>). </p>
<p>Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during, and after the stressful situation. </p>
<p>Results from one multicenter, randomized, placebo-controlled study with methylprednisolone hemisuccinate, an IV corticosteroid, showed an increase in early (at 2 weeks) and late (at 6 months) mortality in patients with cranial <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span> who were determined not to have other clear indications for corticosteroid treatment. High doses of systemic corticosteroids, including SOLU-CORTEF, should not be used for the treatment of <span class="product-label-link" type="condition" conceptid="437409" conceptname="Intracranial injury">traumatic brain injury</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_65251f5e-d959-40e3-828b-ee384938400c"></a><a name="section-6.2"></a><p></p>
<h2>Cardio-renal</h2>
<p class="First">Average and large doses of corticosteroids can cause elevation of blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.</p>
<p>Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>; therefore, therapy with corticosteroids should be used with great caution in these patients. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2da52b3b-b1db-4d2b-b16a-6cff3d9916e8"></a><a name="section-6.3"></a><p></p>
<h2>Endocrine</h2>
<p class="First">Hypothalamic-pituitary adrenal (HPA) axis suppression. Cushing's syndrome, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>. Monitor patients for these conditions with chronic use. Corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Drug induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6d3583df-1577-458c-ade9-c85c86dafd5e"></a><a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fb13acf4-3300-411b-b5e9-faf3ab24b58e"></a><a name="section-6.4.1"></a><p></p>
<h3>General</h3>
<p class="First">Patients who are on corticosteroids are more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> than are healthy individuals. There may be decreased resistance and inability to localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are used. <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> with any pathogen (viral, bacterial, fungal, protozoan or helminthic) in any location of the body may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents.</p>
<p>These <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. Corticosteroids may also mask some signs of current <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. Do not use intra-articularly, intrabursally or for intratendinous administration for <span class="Italics">local</span> effect in the presence of acute local <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_af4d6292-0f32-4c5d-964d-54edaf41f91b"></a><a name="section-6.4.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">Fungal infections</span></h3>
<p class="First">Corticosteroids may exacerbate systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> and therefore should not be used in the presence of such <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> unless they are needed to control drug reactions. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (see <span class="Bold"><a href="#i4i_contraindications_id_2d461d45-2cd3-4efc-b04c-1d6c43d36f9d">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#i4i_section_id_9ee5fbd9-019e-4555-a78a-729c48a11999">PRECAUTIONS, Drug Interactions, Amphotericin B injection and potassium-depleting agents</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_56af3261-8e7a-4cfe-a941-fb93a7cc336e"></a><a name="section-6.4.3"></a><p></p>
<h3>Special pathogens</h3>
<p class="First">Latent disease may be activated or there may be an exacerbation of intercurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to pathogens, including those caused by Amoeba, <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span>, Cryptococus, Mycobacterium, Nocardia, Pneumocystis, Toxoplasma. </p>
<p>It is recommended that latent <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> or active <span class="product-label-link" type="condition" conceptid="438959" conceptname="Amebic infection">amebiasis</span> be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or in any patient with unexplained <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestation</span>. In such patients, corticosteroid-induced <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span> may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe <span class="product-label-link" type="condition" conceptid="4184503" conceptname="Enterocolitis">enterocolitis</span> and potentially fatal gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span>. </p>
<p>Corticosteroids should not be used in <span class="product-label-link" type="condition" conceptid="4202367" conceptname="Cerebral malaria">cerebral malaria</span>. There is currently no evidence of benefit from steroids in this condition. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5e9f7fa9-b4bf-44ec-aa50-ec83fa0e4e23"></a><a name="section-6.4.4"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">Tuberculosis</span></h3>
<p class="First">The use of corticosteroids in active <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> should be restricted to those cases of fulminating or <span class="product-label-link" type="condition" conceptid="4112387" conceptname="Disseminated tuberculosis">disseminated tuberculosis</span> in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen. </p>
<p>If corticosteroids are indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0f56bffd-f6eb-4959-837e-ff65071d73e8"></a><a name="section-6.4.5"></a><p></p>
<h3>Vaccination</h3>
<p class="First"><span class="Bold">Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered. However, the reponse to such vaccines cannot be predicted.</span> Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison's disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ac8786dc-7780-4c89-afd9-bce2a7c8c4a0"></a><a name="section-6.4.6"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral infections</span></h3>
<p class="First">Chicken pox and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span> can have a more serious or even fatal course in pediatric and adult patients on corticosteroids. In pediatric and adult patients who have not had these diseases, particular care should be taken to avoid exposure. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be indicated. If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents should be considered. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d339d04a-bc68-4e3a-8c43-62495190a98f"></a><a name="section-6.4.7"></a><p></p>
<h3>Neurologic</h3>
<p class="First">Reports of severe medical events have been associated with the intrathecal route of administration (see <span class="Bold"><a href="#i4i_p_id_03bb2cf5-181e-4663-be5f-3d29683e30f5">ADVERSE REACTIONS, Neurologic/Psychiatric</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f98ddf31-29d9-402d-9861-7fde5c738ccb"></a><a name="section-6.4.8"></a><p></p>
<h3>Ophthalmic</h3>
<p class="First">Use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to bacteria, fungi, or viruses. The use of oral corticosteroids is not recommended in the treatment of <span class="product-label-link" type="condition" conceptid="374954" conceptname="Optic neuritis">optic neuritis</span> and may lead to an increase in the risk of new episodes. Corticosteroids should be used cautiously in patients with ocular herpes simplex because of <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>. Corticosteroids should not be used in active ocular herpes simplex.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_dfbe1016-17fc-4190-bbf9-e25e530cebe1"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_1a2bb4d9-262d-446b-940b-abb1e702cddf"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">This product, like many other steroid formulations, is sensitive to heat. Therefore, it should not be autoclaved when it is desirable to sterilize the exterior of the vial. The lowest possible dose of corticosteroid should be used to control the condition under treatment. When reduction in dosage is possible, the reduction should be gradual.</p>
<p>Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.</p>
<p>Kaposi's <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a920c21-8590-42e3-b974-86b92872ca94"></a><a name="section-7.2"></a><p></p>
<h2>Cardio-renal</h2>
<p class="First">As <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span> with resultant <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a4193642-bb66-474d-b633-1ba237ac2ac0"></a><a name="section-7.3"></a><p></p>
<h2>Endocrine</h2>
<p class="First">Drug-induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f09ce479-2e7c-4cc2-b6db-06245b5b3b10"></a><a name="section-7.4"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First">Steroids should be used with caution in active or latent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>, fresh intestinal anastomoses, and nonspecific <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, since they may increase the risk of a perforation. Signs of peritoneal irritation following <span class="product-label-link" type="condition" conceptid="4202064" conceptname="Gastrointestinal perforation">gastrointestinal perforation</span> in patients receiving corticosteroids may be minimal or absent. </p>
<p>There is an enhanced effect due to increased metabolism of corticosteroids in patients with cirrhosis.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c0dfb0b3-9017-4443-a5a4-bb08f9769c4c"></a><a name="section-7.5"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First">Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in pediatric patients and the development of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> at any age. Special consideration should be given to patients at increased risk of <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> (i.e., postmenopausal women) before initiating corticosteroid therapy.</p>
<p>Local injection of a steroid into a previously infected site is not usually recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f240d572-491f-47d3-a140-aa02589694b5"></a><a name="section-7.6"></a><p></p>
<h2>Neurologic-psychiatric</h2>
<p class="First">Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See <span class="Bold"><a href="#i4i_dosage_admin_id_83d0b44f-84a2-4c6b-86e4-9fa4991abc5b">DOSAGE AND ADMINISTRATION</a></span>.)</p>
<p>An <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This <span class="product-label-link" type="condition" conceptid="4102023" conceptname="Proximal myopathy">acute myopathy</span> is generalized, may involve ocular and respiratory muscles, and may result in <span class="product-label-link" type="condition" conceptid="444419" conceptname="Tetraparesis">quadriparesis</span>. Elevation of creatinine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.</p>
<p>Psychic derangements may appear when corticosteroids are used, ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations. Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_20345a4d-ac03-4cfd-8c78-99b36868e778"></a><a name="section-7.7"></a><p></p>
<h2>Ophthalmic</h2>
<p class="First">Intraocular pressure may become elevated in some individuals. If steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_f0adc3a3-5ef0-42f9-aafb-c266a0338cf4"></a><a name="section-7.8"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision, to advise any medical attendants that they are taking corticosteroids and to seek medical advice at once should they develop <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </p>
<p>Persons who are on corticosteroids should be warned to avoid exposure to chicken pox or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>. Patients should also be advised that if they are exposed, medical advice should be sought without delay.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_5cd307cf-a22e-4c8a-96d0-cfc64fbc2d50"></a><a name="section-7.9"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_47362502-761e-48fa-9a26-9bf0275234cc"></a><a name="section-7.9.1"></a><p></p>
<h3>Aminoglutethimide</h3>
<p class="First">Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9ee5fbd9-019e-4555-a78a-729c48a11999"></a><a name="section-7.9.2"></a><p></p>
<h3>Amphotericin B injection and potassium-depleting agents</h3>
<p class="First">When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., amphotericin-B, diuretics), patients should be observed closely for development of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f96e974-45ef-426d-8c2e-ac543d6d1bdc"></a><a name="section-7.9.3"></a><p></p>
<h3>Antibiotics</h3>
<p class="First">Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see <span class="Bold"><a href="#i4i_section_id_6fb475f2-2062-4bae-88e7-a9262c00c58c">Drug Interactions, Hepatic Enzyme Inhibitors</a></span>). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_015e0524-1d1c-49a2-a9f7-08924e37c3b7"></a><a name="section-7.9.4"></a><p></p>
<h3>Anticholinesterases</h3>
<p class="First">Concomitant use of anticholinesterase agents and corticosteroids may produce severe <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ff14608f-1374-42bb-9048-a1a909894688"></a><a name="section-7.9.5"></a><p></p>
<h3>Anticoagulants, oral</h3>
<p class="First">Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bb03f975-b251-4287-948c-a44c3d2098d8"></a><a name="section-7.9.6"></a><p></p>
<h3>Antidiabetics</h3>
<p class="First">Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_948c8df2-af03-487f-b632-ee735d2ef371"></a><a name="section-7.9.7"></a><p></p>
<h3>Antitubercular drugs</h3>
<p class="First">Serum concentrations of isoniazid may be decreased. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6e0245a8-53ed-4902-9d3c-e4a0dc8d1cf0"></a><a name="section-7.9.8"></a><p></p>
<h3>Cholestyramine</h3>
<p class="First">Cholestyramine may increase the clearance of corticosteroids. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d694ff0c-b6ec-4a58-a660-d993db871ecb"></a><a name="section-7.9.9"></a><p></p>
<h3>Cyclosporine</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">Increased activity</span> of both cyclosporine and corticosteroids may occur when the two are used concurrently. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been reported with this concurrent use. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b242a740-2234-4eb8-ba20-799e1d4bb5e0"></a><a name="section-7.9.10"></a><p></p>
<h3>Digitalis glycosides</h3>
<p class="First">Patients on digitalis glycosides may be at increased risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> due to <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cbbfa7af-0417-483e-a7a4-1b1bd7b6a128"></a><a name="section-7.9.11"></a><p></p>
<h3>Estrogens, including oral contraceptives</h3>
<p class="First">Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_78850d84-ea00-4355-992a-f589ad830afa"></a><a name="section-7.9.12"></a><p></p>
<h3>Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin)</h3>
<p class="First">Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6fb475f2-2062-4bae-88e7-a9262c00c58c"></a><a name="section-7.9.13"></a><p></p>
<h3>Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin)</h3>
<p class="First">Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3e0110f9-e462-42d6-966c-32292436be8e"></a><a name="section-7.9.14"></a><p></p>
<h3>Ketoconazole</h3>
<p class="First">Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f93b2d8d-4e75-493c-8d07-e87894815f01"></a><a name="section-7.9.15"></a><p></p>
<h3>Nonsteroidal anti-inflammatory agents (NSAIDs)</h3>
<p class="First">Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>. The clearance of salicylates may be increased with concurrent use of corticosteroids. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2e5e6323-35e2-42ad-ba84-4f844f2917c6"></a><a name="section-7.9.16"></a><p></p>
<h3>Skin tests</h3>
<p class="First">Corticosteroids may suppress reactions to skin tests. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_06e8d3c0-5aa0-4e78-a893-a025b2754811"></a><a name="section-7.9.17"></a><p></p>
<h3>Vaccines</h3>
<p class="First">Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see <span class="Bold"><a href="#i4i_section_id_0f56bffd-f6eb-4959-837e-ff65071d73e8">WARNINGS, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span>, Vaccination</a></span>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_32fd6f80-b379-4edb-be07-335103ffc65d"></a><a name="section-7.10"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No adequate studies have been conducted in animals to determine whether corticosteroids have a potential for carcinogenesis or mutagenesis. </p>
<p>Steroids may increase or decrease motility and number of spermatozoa in some patients. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_8addbed9-3d11-48a4-a14c-b8245bfa962b"></a><a name="section-7.11"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_2ab4b8de-662b-4477-92a3-c0b6a5f7fc6f"></a><a name="section-7.11.1"></a><p></p>
<h3>Teratogenic effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_22b6eba1-69fc-47fd-b89c-f52392f69da3"></a><a name="section-7.11.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> in the offspring. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received corticosteroids during pregnancy should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_f58fbb94-7874-4830-bfd6-4229b1c543c8"></a><a name="section-7.12"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from corticosteroids, a decision should be made whether to continue nursing, or discontinue the drug, taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_42eebec1-6791-4987-909c-1a3a1bc4f1ca"></a><a name="section-7.13"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">This product contains benzyl alcohol as a preservative. Benzyl alcohol, a component of this product, has been associated with serious adverse events and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, particularly in pediatric patients. The "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndrome", (characterized by central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> respirations, and high levels of benzyl alcohol and its metabolites found in the blood and urine) has been associated with benzyl alcohol dosages &gt;99 mg/kg/day in neonates and low-birth-weight neonates. Additional symptoms may include gradual neurological deterioration, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, hematologic abnormalities, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin breakdown</span>, hepatic and <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>. Although normal therapeutic doses of this product deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndrome", the minimum amount of benzyl alcohol at which toxicity may occur is not known. Premature and low-birth-weight infants, as well as patients receiving high dosages, may be more likely to develop toxicity. Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources. </p>
<p>The efficacy and safety of corticosteroids in the pediatric population are based on the well-established course of effect of corticosteroids which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> (&gt;2 years of age), and aggressive <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> and <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemias</span> (&gt;1 month of age). Other indications for pediatric use of corticosteroids, e.g., severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, are based on adequate and well-controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations. </p>
<p>The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see <span class="Bold"><a href="#i4i_adverse_effects_id_12835ccc-8444-40f7-b89b-2463e6c472e0">ADVERSE REACTIONS</a></span>). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, psychosocial disturbances, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataracts</span>, and <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>. Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (i.e., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_4c3ac9b9-d22d-4f3d-8be4-f1ff57239dea"></a><a name="section-7.14"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_12835ccc-8444-40f7-b89b-2463e6c472e0"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions have been reported with SOLU-CORTEF or other corticosteroids:</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span>: Allergic or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>. </p>
<p>Cardiovascular: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, cardiac enlargement, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="4057039" conceptname="Fat embolism">fat embolism</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span> in premature infants, <span class="product-label-link" type="condition" conceptid="4107225" conceptname="Rupture of heart">myocardial rupture</span> following recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (see <span class="Bold"><a href="#i4i_warnings_id_294eea5c-daf0-43f7-88d9-5ecf0c3316c1">WARNINGS</a></span>), <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>. </p>
<p>Dermatologic: <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span>, <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">allergic dermatitis</span>, burning or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> (especially in the perineal area, after intravenous injection), cutaneous and subcutaneous <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, dry scaly skin, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span> and <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, hyperpigmentation, hypopigmentation, impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, sterile <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>. </p>
<p>Endocrine: Decreased carbohydrate and glucose tolerance, development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">cushingoid</span> state, <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>, <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, increased requirements for insulin or oral hypoglycemic agents in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, manifestations of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery, or illness), suppression of growth in pediatric patients. </p>
<p>Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte disturbances</span>: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> in susceptible patients, <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">hypokalemic alkalosis</span>, potassium loss, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>. </p>
<p>Gastrointestinal: Abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, bowel/bladder dysfunction (after intrathecal administration), elevation in serum liver enzyme levels (usually reversible upon discontinuation), <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span> with possible perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, perforation of the small and large intestine (particularly in patients with <span class="product-label-link" type="condition" conceptid="4074815" conceptname="Inflammatory bowel disease">inflammatory bowel disease</span>), ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>. </p>
<p>Metabolic: Negative nitrogen balance due to protein catabolism. </p>
<p>Musculoskeletal: <span class="product-label-link" type="condition" conceptid="77650" conceptname="Aseptic necrosis of bone">Aseptic necrosis</span> of femoral and humeral heads, Charcot-like <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span>, loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones, postinjection flare (following intra-articular use), <span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">steroid myopathy</span>, <span class="product-label-link" type="condition" conceptid="76202" conceptname="Non-traumatic rupture of Achilles tendon">tendon rupture</span>, vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span>. </p>
<p>Neurologic/Psychiatric: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (<span class="product-label-link" type="condition" conceptid="312902" conceptname="Benign intracranial hypertension">pseudotumor cerebri</span>) usually following discontinuation of treatment, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, psychic disorders, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>. <span class="product-label-link" type="condition" conceptid="4218912" conceptname="Arachnoiditis">Arachnoiditis</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, <span class="product-label-link" type="condition" conceptid="4081615" conceptname="Paraparesis">paraparesis</span>/<span class="product-label-link" type="condition" conceptid="192606" conceptname="Paraplegia">paraplegia</span>, and <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbances</span> have occurred after intrathecal administration (see <span class="Bold"><a href="#i4i_section_id_d339d04a-bc68-4e3a-8c43-62495190a98f">WARNINGS, Neurologic</a></span>). </p>
<p>Ophthalmic: <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">Exophthalmoses</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, rare instances of <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span> associated with periocular injections. </p>
<p>Other: Abnormal fat deposits, decreased resistance to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">hiccups</span>, increased or decreased motility and number of spermatozoa, <span class="product-label-link" type="condition" conceptid="4318388" conceptname="Injection site infection">injection site infections</span> following non-sterile administration (see <a href="#i4i_warnings_id_294eea5c-daf0-43f7-88d9-5ecf0c3316c1">WARNINGS</a>), <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">moon face</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_be63f6f8-796c-4557-b314-65d3b7acf1da"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Treatment of acute overdosage is by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of the corticosteroid may be reduced only temporarily, or alternate day treatment may be introduced. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_83d0b44f-84a2-4c6b-86e4-9fa4991abc5b"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">NOTE: CONTAINS BENZYL ALCOHOL (see <a href="#i4i_warnings_id_294eea5c-daf0-43f7-88d9-5ecf0c3316c1">WARNINGS</a> and <a href="#i4i_pediatric_use_id_42eebec1-6791-4987-909c-1a3a1bc4f1ca">PRECAUTIONS: Pediatric Use</a>)</span></p>
<p><span class="Bold">Because of possible physical incompatibilities, SOLU-CORTEF should not be diluted or mixed with other solutions.</span></p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. </p>
<p>This preparation may be administered by intravenous injection, by intravenous infusion, or by intramuscular injection, the preferred method for initial emergency use being intravenous injection. Following the initial emergency period, consideration should be given to employing a longer acting injectable preparation or an oral preparation.</p>
<p>Therapy is initiated by administering SOLU-CORTEF Sterile Powder intravenously over a period of 30 seconds (e.g., 100 mg) to 10 minutes (e.g., 500 mg or more). In general, high dose corticosteroid therapy should be continued only until the patient's condition has stabilized-usually not beyond 48 to 72 hours. When high dose hydrocortisone therapy must be continued beyond 48–72 hours, <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span> may occur. Under such circumstances it may be desirable to replace SOLU-CORTEF with a corticoid such as methylprednisolone sodium succinate which causes little or no <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>.</p>
<p>The initial dose of SOLU-CORTEF Sterile Powder is 100 mg to 500 mg, depending on the specific disease entity being treated. However, in certain overwhelming, acute, life-threatening situations, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. </p>
<p>This dose may be repeated at intervals of 2, 4 or 6 hours as indicated by the patient's response and clinical condition. </p>
<p>It Should Be Emphasized that Dosage Requirements are Variable and Must Be Individualized on the Basis of the Disease Under Treatment and the Response of the Patient. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage that maintains an adequate clinical response is reached. Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient's condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. </p>
<p>In the treatment of acute exacerbations of <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, daily doses of 800 mg of hydrocortisone for a week followed by 320 mg every other day for one month are recommended (see <span class="Bold"><a href="#i4i_section_id_f240d572-491f-47d3-a140-aa02589694b5">PRECAUTIONS, Neuro-psychiatric</a></span>). </p>
<p>In pediatric patients, the initial dose of hydrocortisone may vary depending on the specific disease entity being treated. The range of initial doses is 0.56 to 8 mg/kg/day in three or four divided doses (20 to 240 mg/m<span class="Sup">2</span>bsa/day). For the purpose of comparison, the following is the equivalent milligram dosage of the various glucocorticoids: </p>
<a name="id_c95488c7-174a-4baf-9a86-8b58f42de12b"></a><table>
<col align="left" width="50%">
<col align="left" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top">Cortisone, 25</td>
<td class="Rrule" align="left" valign="top">Triamcinolone, 4</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Hydrocortisone, 20</td>
<td class="Rrule" align="left" valign="top">Paramethasone, 2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Prednisolone, 5</td>
<td class="Rrule" align="left" valign="top">Betamethasone, 0.75</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Prednisone, 5</td>
<td class="Rrule" align="left" valign="top">Dexamethasone, 0.75</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">Methylprednisolone, 4</td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives intramuscularly or into joint spaces, their relative properties may be greatly altered.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_24bf4f44-7e97-421e-b23d-150b66946449"></a><a name="section-10.1"></a><p></p>
<h2>DIRECTIONS FOR USING THE ACT-O-VIAL SYSTEM</h2>
<ol>
<li>Press down on plastic activator to force diluent into the lower compartment.</li>
<li>Gently agitate to effect solution.</li>
<li>Remove plastic tab covering center of stopper.</li>
<li>Sterilize top of stopper with a suitable germicide.</li>
<li>Insert needle <span class="Bold">squarely through center </span>of stopper until tip is just visible. Invert vial and withdraw dose.</li>
</ol>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2b4c961-363d-49fe-b354-d59b39fd517a&amp;name=b2b4c961-363d-49fe-b354-d59b39fd517a-02.jpg"></div>
<p class="First"><span class="Bold">Further dilution is not necessary for intravenous or intramuscular injection. For intravenous infusion, </span>first prepare solution as just described. The <span class="Bold">100 mg </span>solution may then be added to 100 to 1000 mL of 5% dextrose in water (or isotonic saline solution or 5% dextrose in isotonic saline solution if patient is not on sodium restriction). The <span class="Bold">250 mg </span>solution may be added to 250 to 1000 mL, the <span class="Bold">500 mg </span>solution may be added to 500 to 1000 mL and the <span class="Bold">1000 mg </span>solution to 1000 mL of the same diluents. In cases where administration of a small volume of fluid is desirable, 100 mg to 3000 mg of SOLU-CORTEF may be added to 50 mL of the above diluents. The resulting solutions are stable for at least 4 hours and may be administered either directly or by IV piggyback.</p>
<p>When reconstituted as directed, pH's of the solutions range from 7 to 8 and the tonicities are: 100 mg ACT-O-VIAL, .36 osmolar; 250 mg ACT-O-VIAL, 500 mg ACT-O-VIAL, and the 1000 mg ACT-O-VIAL, .57 osmolar. (Isotonic saline=.28 osmolar.)</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_d198c301-3054-44f7-9b68-de95819816e7"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">SOLU-CORTEF Sterile Powder is available in the following packages:</p>
<a name="id_f3abbac5-f2bc-4eca-ac60-7c9041c82b86"></a><table>
<col align="left" width="50%">
<col align="left" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top"><span class="Bold">100 mg ACT-O-VIAL (Single-Dose Vial)</span></td>
<td align="left" valign="top"><span class="Bold">250 mg ACT-O-VIAL (Single-Dose Vial)</span></td>
</tr>
<tr>
<td align="left" valign="top">         <span class="Bold">2 mL</span>—NDC 0009-0900-13</td>
<td align="left" valign="top">         <span class="Bold">2 mL</span>—NDC 0009-0909-08</td>
</tr>
<tr>
<td align="left" valign="top">
<span class="Bold">25 × 2 mL</span>—NDC 0009-0900-20</td>
<td align="left" valign="top">
<span class="Bold">25 × 2 mL</span>—NDC 0009-0909-16</td>
</tr>
<tr><td align="left" colspan="2" valign="top">
<span class="Bold">500 mg ACT-O-VIAL (Single-Dose Vial)</span>—NDC 0009-0912-05</td></tr>
<tr class="Botrule Last"><td align="left" colspan="2" valign="top">
<span class="Bold">1000 mg ACT-O-VIAL (Single-Dose Vial)</span>—NDC 0009-0920-03</td></tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_2d8396d4-a0e7-424b-9a5c-63c798fe5093"></a><a name="section-11.1"></a><p></p>
<h2>STORAGE CONDITIONS</h2>
<p class="First">Store unreconstituted product at controlled room temperature 20° to 25°C (68° to 77°F).</p>
<p>Store solution at controlled room temperature 20° to 25°C (68° to 77°F) and protect from light. Use solution only if it is clear. Unused solution should be discarded after 3 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a93938b6-7487-40b8-a226-72e7224ef00d"></a><a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p><img alt="Company Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2b4c961-363d-49fe-b354-d59b39fd517a&amp;name=b2b4c961-363d-49fe-b354-d59b39fd517a-03.jpg"></p>
<p>LAB-0121-8.0<br>July 2010</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_adb65c48-08bc-4629-b4fe-4b6b2403d5eb"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC: 55154-3925-5</p>
<p>Solu-Cortef<span class="Sup">®</span></p>
<p>100 mg*</p>
<p>Hydrocortisone Sodium Succinate for Injection, USP</p>
<p>5-2 mL Act-O-Vial<span class="Sup">®</span> Systems</p>
<div class="Figure"><img alt="Bag Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2b4c961-363d-49fe-b354-d59b39fd517a&amp;name=b2b4c961-363d-49fe-b354-d59b39fd517a-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SOLU-CORTEF 		
					</strong><br><span class="contentTableReg">hydrocortisone sodium succinate injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-3925(NDC:0009-0900)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVASCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>hydrocortisone sodium succinate</strong> (hydrocortisone) </td>
<td class="formItem">hydrocortisone</td>
<td class="formItem">100 mg  in 2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS</strong></td>
<td class="formItem">0.8 mg  in 2 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium phosphate, dibasic</strong></td>
<td class="formItem">8.73 mg  in 2 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>benzyl alcohol</strong></td>
<td class="formItem">18.1 mg  in 2 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-3925-5</td>
<td class="formItem">5  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA009866</td>
<td class="formItem">04/27/1955</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-3925)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b2b4c961-363d-49fe-b354-d59b39fd517a</div>
<div>Set id: b2b4c961-363d-49fe-b354-d59b39fd517a</div>
<div>Version: 1</div>
<div>Effective Time: 20120516</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
